{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T11:41:38Z","timestamp":1782042098119,"version":"3.54.5"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the differential effect of tumor necrosis factor inhibitor (TNFi) therapies and presence or absence of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) on the incidence of psoriasis (PsO) in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic nonbacterial osteomyelitis (CNO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective cohort study from 2008 to 2020. TNFi and DMARD exposures were dichotomized as ever\/never. The primary outcome was incident PsO. Incidence rates (IRs) of PsO were stratified by underlying diagnosis, TNFi agent, and DMARD use. Poisson regression was used to assess the IR ratios (IRRs) between exposure groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 5088 children who met the inclusion criteria: 3794 (75%) had IBD, 1189 (23%) had JIA, and 105 (2%) had CNO. Of the 2023 children with TNFi exposure, 613 (30%) and 1410 (70%) were with or without a DMARD, respectively. When controlling for DMARD, sex, and family history of PsO, the IRR of developing PsO in patients exposed to adalimumab (ADA) was 2.70 times higher (95% CI 1.53-4.75; <jats:italic>P<\/jats:italic> &lt; 0.001) than those who did not receive any TNFi treatment. IRR was lower, but not significantly different, for patients exposed to infliximab (IFX; IRR 2.34, 95% CI 1.56-3.51; <jats:italic>P<\/jats:italic> &lt; 0.001) and etanercept (ETN; IRR 2.21; 95% CI 1.17-4.21; <jats:italic>P<\/jats:italic> = 0.006) compared to TNFi-unexposed patients. IRR of TNFi exposure was lower by 0.25 (<jats:italic>P<\/jats:italic> &lt; 0.001) in DMARD-exposed patients compared to non\u2013DMARD-exposed patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IRR of TNFi-induced PsO was not significantly different among ADA, IFX, and ETN. However, for patients with exposure to any of the TNFi evaluated, the IRR was significantly lower in those also exposed to a DMARD.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.211359","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T12:25:15Z","timestamp":1650025515000},"page":"935-941","source":"Crossref","is-referenced-by-count":5,"title":["Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs"],"prefix":"10.3899","volume":"49","author":[{"given":"Katelyn","family":"Baggett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-4871","authenticated-orcid":false,"given":"Timothy G.","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-9984","authenticated-orcid":false,"given":"Zachary","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7991-0514","authenticated-orcid":false,"given":"Lisa H.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-0443","authenticated-orcid":false,"given":"Pamela F.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"key":"2022072810450892000_49.8.935.1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90398-0"},{"key":"2022072810450892000_49.8.935.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90430-3"},{"key":"2022072810450892000_49.8.935.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.5.293"},{"key":"2022072810450892000_49.8.935.4","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1076793"},{"key":"2022072810450892000_49.8.935.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.07.012"},{"key":"2022072810450892000_49.8.935.6","doi-asserted-by":"publisher","DOI":"10.1259\/dmfr\/23060413"},{"key":"2022072810450892000_49.8.935.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.039"},{"key":"2022072810450892000_49.8.935.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03031.x"},{"key":"2022072810450892000_49.8.935.9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13555-016-0117-6","article-title":"Systemic treatment of pediatric psoriasis: a review","volume":"6","author":"Napolitano","year":"2016","journal-title":"Dermatol Ther"},{"key":"2022072810450892000_49.8.935.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01521.x"},{"key":"2022072810450892000_49.8.935.11","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31828390ba"},{"key":"2022072810450892000_49.8.935.12","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181f3d9ab"},{"key":"2022072810450892000_49.8.935.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01267.x"},{"key":"2022072810450892000_49.8.935.14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/pde.13081","article-title":"Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents","volume":"34","author":"Eickstaedt","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"2022072810450892000_49.8.935.15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jdcr.2018.06.008","article-title":"Case series of psoriasis associated with tumor necrosis factor-\u03b1 inhibitors in children with chronic recurrent multifocal osteomyelitis","volume":"4","author":"Campbell","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2022072810450892000_49.8.935.16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/acr.24100","article-title":"Psoriasis associated with tumor necrosis factor inhibitors in children with inflammatory diseases","volume":"73","author":"Buckley","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2022072810450892000_49.8.935.17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pde.13859","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis in juvenile idiopathic arthritis patients","volume":"36","author":"Groth","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"2022072810450892000_49.8.935.18","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: a decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2022072810450892000_49.8.935.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"2022072810450892000_49.8.935.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.014"},{"key":"2022072810450892000_49.8.935.21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1346-8138.12465","article-title":"Comorbidities and health-related quality of life in Spanish patients with moderate to severe psoriasis: a cross-sectional study (Arizona study)","volume":"41","author":"Sanchez-Carazo","year":"2014","journal-title":"J Dermatol"},{"key":"2022072810450892000_49.8.935.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202347"},{"key":"2022072810450892000_49.8.935.23","first-page":"1","article-title":"Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee","volume":"854","year":"1995","journal-title":"World Health Organ Tech Rep Ser"},{"key":"2022072810450892000_49.8.935.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.029"},{"key":"2022072810450892000_49.8.935.25","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2022072810450892000_49.8.935.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.23835"},{"key":"2022072810450892000_49.8.935.27","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.205"},{"key":"2022072810450892000_49.8.935.28","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000757"},{"key":"2022072810450892000_49.8.935.29","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s10620-018-4921-y","article-title":"Anti-tumor necrosis factor-\u03b1-induced dermatological complications in a large cohort of inflammatory bowel disease patients","volume":"63","author":"Andrade","year":"2018","journal-title":"Dig Dis Sci"},{"key":"2022072810450892000_49.8.935.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220097"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.211359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T17:48:17Z","timestamp":1659030497000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.211359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,7,28]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.3899\/jrheum.211359"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.211359","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}